Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)

Background: Management of Non-Small Cell Lung Cancer (NSCLC) patients with oligoprogression remains controversial. There is limited data to support the strategy of Stereotactic Ablative Radiotherapy (SABR) targeting the oligoprogressive disease in combination with ongoing systemic treatment. We aim...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Houda Bahig, Marion Tonneau, Normand Blais, Philip Wong, Edith Filion, Marie-Pierre Campeau, Toni Vu, Afnan Al-Saleh, Mustapha Tehfé, Marie Florescu, David Roberge, Laura Masucci, Corentin Richard, Cynthia Menard, Bertrand Routy
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2022-03-01
Saila:	Clinical and Translational Radiation Oncology
Gaiak:	Stereotactic body radiation therapy Non-Small Cell Lung Cancer Oligoprogression
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2405630821001075
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!